No Data
No Data
No Data
Eisai Projects Major Growth for Alzheimer's Therapy Leqembi
Biogen Partner Eisai Begins FDA Submissions for Injectable Alzheimer's Therapy
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (Lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Eisai Co., Ltd. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.
Eli Lilly Alzheimer's Therapy Set for June FDA AdCom Meeting
Biogen Says Uptake for Alzheimer's Therapy Is Improving
Biogen's Alzheimer's Drug to Cost $3.5B for Medicare in 2025: Report
No Data